SCHEMBL17100640

SCHEMBL17100640

COc1ccc(S(=O)(=O)N2CCN(c3nc(COc4cccc(Cl)c4)no3)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.52
ALDH1A1 P00352 3/20 0.52
TSHR P16473 2/20 0.52
MAPK1 P28482 2/20 0.52
KMT2A Q03164 2/20 0.47
PKM P14618 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
POLB P06746 2/20 0.45
NPC1 O15118 1/20 0.45
PKLR P30613 1/20 0.45
RAB9A P51151 1/20 0.45
MAPT P10636 3/20 0.44
HTT P42858 1/20 0.44
HSD11B1 P28845 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TP53 P04637 1/20 0.43
GBA1 P04062 1/20 0.43
PTPN11 Q06124 1/20 0.43
SLC6A9 P48067 1/20 0.42
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100741 0.90 PKM (0.54) LMNAALDH1A1TSHRMAPK1KMT2A
SCHEMBL17100632 0.89 PKM (0.56) LMNAALDH1A1TSHRKMT2APKM
SCHEMBL17101017 0.86 ALDH1A1 (0.61) LMNAALDH1A1TSHRMAPK1KMT2A
SCHEMBL17100814 0.85 HSD11B1 (0.47) LMNAALDH1A1TSHRKMT2APKM
SCHEMBL17100757 0.84 GBA1 (0.52) LMNAALDH1A1TSHRKMT2APKM
SCHEMBL17100954 0.84 PKM (0.56) LMNAALDH1A1TSHRKMT2APKM
SCHEMBL17100767 0.83 CCR6 (0.49) LMNAALDH1A1TSHRKMT2APKM
SCHEMBL17101010 0.82 PKM (0.56) LMNAALDH1A1TSHRMAPK1KMT2A
SCHEMBL17115045 0.81 PKM (0.57) LMNAALDH1A1TSHRKMT2APKM
SCHEMBL17100842 0.81 ALDH1A1 (0.59) LMNAALDH1A1TSHRMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT LMNA 760/4885ALDH1A1 482/4885TSHR 1833/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT LMNA 748/4885ALDH1A1 561/4885TSHR 1962/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT LMNA 760/4885ALDH1A1 482/4885TSHR 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.